• 1
    Mukerjee D, St George D, Coleiro B, Knight C, Denton CP, Davar J, et al.Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach.Ann Rheum Dis2003;62:108893.
  • 2
    Hachulla E, Gressin V, Guillevin L, Carpentier P, Diot E, Sibilia J, et al.Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study.Arthritis Rheum2005;52:3792800.
  • 3
    Hesselstrand R, Wildt M, Ekmehag B, Wuttge DM, Scheja A.Survival in patients with pulmonary arterial hypertension associated with systemic sclerosis from a Swedish single centre: prognosis still poor and prediction difficult.Scand J Rheumatol2011;40:12732.
  • 4
    Komocsi A, Vorobcsuk A, Faludi R, Pinter T, Lenkey Z, Kolto G, et al.The impact of cardiopulmonary manifestations on the mortality of SSc: a systematic review and meta-analysis of observational studies.Rheumatology (Oxford)2012;51:102736.
  • 5
    Chung L, Liu J, Parsons L, Hassoun PM, McGoon M, Badesch DB, et al.Characterization of connective tissue disease associated pulmonary arterial hypertension from the REVEAL registry: identifying systemic sclerosis as a unique phenotype.Chest2010;138:138394.
  • 6
    Williams MH, Das C, Handler CE, Akram MR, Davar J, Denton CP, et al.Systemic sclerosis associated pulmonary hypertension: improved survival in the current era.Heart2006;92:92632.
  • 7
    Campo A, Mathai SC, Le Pavec J, Zaiman AL, Hummers LK, Boyce D, et al.Hemodynamic predictors of survival in scleroderma-related pulmonary arterial hypertension.Am J Respir Crit Care Med2010;182:25260.
  • 8
    Condliffe R, Kiely DG, Peacock AJ, Corris PA, Gibbs JS, Vrapi F, et al.Connective tissue disease associated pulmonary arterial hypertension in the modern treatment era.Am J Respir Crit Care Med2009;179:1517.
  • 9
    Galie N, Rubin L, Hoeper M, Jansa P, Al-Hiti H, Meyer G, et al.Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial.Lancet2008;371:2093100.
  • 10
    Hachulla E, Launay D, Yaici A, Berezne A, de Groote P, Sitbon O, et al.Pulmonary arterial hypertension associated with systemic sclerosis in patients with functional class II dyspnoea: mild symptoms but severe outcome.Rheumatology (Oxford)2010;49:9404.
  • 11
    Humbert M, Yaici A, de Groote P, Montani D, Sitbon O, Launay D, et al.Screening for pulmonary arterial hypertension in patients with systemic sclerosis: clinical characteristics at diagnosis and long-term survival.Arthritis Rheum2011;63:352230.
  • 12
    Fischer A, Bull TM, Steen VD.Practical approach to screening for scleroderma-associated pulmonary arterial hypertension.Arthritis Care Res (Hoboken)2012;64:30310.
  • 13
    Hinchcliff M, Fischer A, Schiopu E, Steen VD.Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS): baseline characteristics and description of study population.J Rheumatol2011;38:21729.
  • 14
    Ngian GS, Stevens W, Prior D, Gabbay E, Roddy J, Tran A, et al.Predictors of mortality in connective tissue disease-associated pulmonary arterial hypertension: a cohort study.Arthritis Res Ther2012;14:R213.
  • 15
    Chandra S, Shah SJ, Thenappan T, Archer SL, Rich S, Gomberg-Maitland M.Carbon monoxide diffusing capacity and mortality in pulmonary arterial hypertension.J Heart Lung Transplant2010;29:1817.